704910-45-2

Basic information

• Product Name: Zinc, chloro-2-cyclohexen-1-yl-
• CAS NO: 704910-45-2
• Molecular Formula: C6H9ClZn
• Molecular Weight: 181.98
• Mol File: 704910-45-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Zinc, chloro-2-cyclohexen-1-yl-(CAS DataBase Reference)
• NIST Chemistry Reference: Zinc, chloro-2-cyclohexen-1-yl-(704910-45-2)
• EPA Substance Registry System: Zinc, chloro-2-cyclohexen-1-yl-(704910-45-2)

Safety Data

• Hazardous Substances Data: 704910-45-2(Hazardous Substances Data)

Upstream product

• 2441-97-6 3-chloro-cyclohexene 
• 7440-66-6 zinc 
• 1165952-91-9 cyclohexa-1,3-diene 
• 112520-99-7 tributyl(cyclohex-2-en-1-yl)stannane 
• 7646-85-7 zinc(II) chloride 

Downstream Products

• 1064062-07-2 (4S)-4-{(S)-[(S)-cyclohex-2-enyl](hydroxy)methyl}-4-{[(2-methoxyethoxy)methoxy]methyl}-3-(4-methoxybenzyl)oxazolidin-2-one 
• 1039750-76-9 (S)-2-methyl-propane-2-sulfinic acid [(S)-1-((S)-cyclohex-2-enyl)-1-phenylpropyl]amide 
• 1039750-75-8 (S)-2-methyl-propane-2-sulfinic acid [(S)-1-(4-bromo-phenyl)-1-((S)-cyclohex-2-enyl)ethyl]amide 
• 1039750-74-7 (S)-2-methyl-propane-2-sulfinic acid [(S)-1-((S)-cyclohex-2-enyl)-1-phenylethyl]amide 
• 1039750-73-6 (S)-2-methyl-propane-2-sulfinic acid [(S)-((S)-cyclohex-2-enyl)-(furan-2-yl)methyl]amide 
• 1039750-72-5 (S)-2-methyl-propane-2-sulfinic acid [(R)-1-((S)-cyclohex-2-enyl)propyl]amide 
• 1039750-71-4 (S)-2-methyl-propane-2-sulfinic acid [(R)-cyclohexyl-((S)-cyclohex-2-enyl)methyl]amide 
• 1039750-70-3 (S)-2-methyl-propane-2-sulfinic acid [(S)-(4-fluoro-2-bromo-phenyl)-((S)-cyclohex-2-enyl)methyl]amide 
• 1039750-69-0 (S)-2-methyl-propane-2-sulfinic acid [(S)-(4-methoxy-phenyl)-((S)-cyclohex-2-enyl)methyl]amide 
• 1039750-68-9 (S)-2-methyl-propane-2-sulfinic acid [(S)-(4-methyl-phenyl)-((S)-cyclohex-2-enyl)methyl]amide 
• 1039750-67-8 (S)-2-methyl-propane-2-sulfinic acid [(S)-((S)-cyclohex-2-enyl)-(4-fluoro-phenyl)methyl]amide 
• 1039750-66-7 (S)-2-methyl-propane-2-sulfinic acid [(S)-(4-bromo-phenyl)-((S)-cyclohex-2-enyl)methyl]amide 
• 704910-39-4 (3R,3aS,7aR)-3-((S)-(S)-Cyclohex-2-enyl-hydroxy-methyl)-2-(4-methoxy-benzyl)-3a,5,5-trimethyl-1-oxo-octahydro-4-oxa-2-aza-5-sila-indene-3-carboxylic acid methyl ester 

Relevant articles and documents

PROTEASOME INHIBITING ?-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS

The present invention relates generally to proteasome inhibiting β-lactam compounds useful for the treatment of cancer and neurodegenerative disorders. The invention also provides pharmaceutical compositions and extended release formulations of said compounds, and medical uses of said compounds and/or pharmaceutical compositions to treat cancer and neurodegenerative disorders.

TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF

The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing Salinosporamide A and its analogs from a compound of formula (V).

Simple stereocontrolled synthesis of salinosporamide A

A simple and effective stereocontrolled synthesis of salinosporamide A (1) has been developed which follows the pathway outlined in the Figure. The process, the first total synthesis of salinosporamide A, is capable of providing the compound in substantial quantities for further biological studies. In addition to the method of Scheme I, the present invention also includes several novel synthetic intermediate compounds, several intermediate steps of the preferred synthetic process; and the uses of these compounds in the preparation of synthetic derivatives of the compound Salinosporamide A. Salinosporamide A is of special interest as a synthetic target because of its protein in vitro cytotoxic activity against many tumor cell lines (IC50 values of 10 nM or less).